South & Central America Human Vaccine Adjuvants Market
No. of Pages: 91 | Report Code: BMIRE00030544 | Category: Life Sciences
No. of Pages: 91 | Report Code: BMIRE00030544 | Category: Life Sciences
The South & Central America human vaccine adjuvants market was valued at US$ 63.62 million in 2022 and is expected to reach US$ 185.34 million by 2030; it is estimated to register a CAGR of 14.3% from 2022 to 2030. Rising Trend of Personalized Vaccines Fuels South & Central America Human Vaccine Adjuvants Market
Precision or personalized vaccines are a growing trend in the South & Central America human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders. Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the South & Central America human vaccine adjuvants market.South & Central America Human Vaccine Adjuvants Market Overview
Brazil is among the largest countries in South & Central America. According to the Brazilian Institute of Geography and Statistics (IBGE), Brazil has a unified healthcare system (SUS) that caters health services to approximately 72% of the population. SUS provides free medication and promotes national vaccination programs mostly focused on older adults and children. According to the International Trade Administration, Brazilian public laboratories and universities play a key role in research and development for diagnostic kits, drugs, and vaccines.
According to the Global Burden of Disease study published in October 2020, Brazil has an increasing prevalence of various chronic and infectious diseases, such as tuberculosis, stroke, influenza, chronic obstructive pulmonary disease (COPD), Alzheimer's disease, and diabetes. Similarly, according to the CDC, mosquito-borne diseases (chikungunya, dengue, malaria, yellow fever, and Zika) are endemic in Brazil. Thus, the application of human vaccine adjuvants will increase due to the increasing disease burden in Brazil.
Rising healthcare expenditures and an increasing geriatric population are propelling the development of human vaccine adjuvants. According to the World Bank, Brazil's healthcare expenditure was 10.31% of the GDP in 2020, a significant increase from 8.91% in 2015. Additionally, the rising geriatric population in the country is at high risk for various diseases and disabilities. The OECD reported that 21.9% of the population in Brazil is expected to be 65 years and above by 2050, a significant increase from 8.9% in 2017. Thus, the increasing geriatric population, infectious disease prevalence, and health expenditure would propel the growth of Brazil's human vaccine adjuvants market in the coming years.
Strategic insights for the South & Central America Human Vaccine Adjuvants provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 63.62 Million |
| Market Size by 2030 | US$ 185.34 Million |
| Global CAGR (2022 - 2030) | 14.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | South and Central America
|
| Market leaders and key company profiles |
The geographic scope of the South & Central America Human Vaccine Adjuvants refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
1. Novartis AG
2. CSL Ltd
3. Seppic SA
4. Croda International Plc
5. Novavax Inc
6. Phibro Animal Health Corp
The South & Central America Human Vaccine Adjuvants Market is valued at US$ 63.62 Million in 2022, it is projected to reach US$ 185.34 Million by 2030.
As per our report South & Central America Human Vaccine Adjuvants Market, the market size is valued at US$ 63.62 Million in 2022, projecting it to reach US$ 185.34 Million by 2030. This translates to a CAGR of approximately 14.3% during the forecast period.
The South & Central America Human Vaccine Adjuvants Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Human Vaccine Adjuvants Market report:
The South & Central America Human Vaccine Adjuvants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Human Vaccine Adjuvants Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Human Vaccine Adjuvants Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South & Central America Human Vaccine Adjuvants Market
